Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Anushree C. Shirali, Mark Anthony Perazella, Scott N. Gettinger · American Journal of Kidney Diseases · 2016
Cited by 284 works. doi:10.1053/j.ajkd.2016.02.057
Authors
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
- B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
- The PD‐1 pathway in tolerance and autoimmunity
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- Anti-CTLA4 Antibody–Induced Lupus Nephritis